For suspected or existing coronary artery disease. ANDA 210524, held by Ionetix. Ammonia N-13.
As of Nov 16, 2026, ANDA 210524 (Ammonia N 13), held by Ionetix, was first approved by FDA on Dec 21, 2018, with 1 approved supplement and 0 published complete response letters.
Ammonia N 13 Injection is indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. Ammonia N 13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 21, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ammonia N 1322.5mCi-225mCi/6ML (3.75-37.5mCi/ML) · injectable;intravenous | Ammonia N-13 | Rx |
| Jan 31, 2020 | Supplement 1Manufacturing | Approved | None posted |
| Dec 21, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters